{"filings":[{"id":808437,"accession_number":"0001193125-26-253851","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2026-06-02T21:15:12+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.","Decision does not affect prior settlements for CINVANTI or APONVIE injectable emulsions.","Heron intends to appeal to the Federal Circuit, a court specializing in patent disputes.","CEO Craig Collard said company will vigorously pursue appeal and all available remedies.","Litigation with Azurity (formerly Slayback) involves a generic version of CINVANTI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-02","daily_digest_url":"/daily/2026-06-02","daily_digest_rank":8},{"id":99039,"accession_number":"0001193125-26-215752","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $34.7M vs $38.9M YoY; Acute Care franchise up 32% led by ZYNRELEF (+27%) and APONVIE (+50%).","Oncology net revenue $21.1M (-26.3% YoY) as CINVANTI declined 20.2% and SUSTOL wind-down continued.","Reaffirmed FY2026 guidance: net revenue $173-183M and Adjusted EBITDA $10-20M; cash $44.8M.","Settled CINVANTI patent litigation with Baxter; case dismissed April 28, 2026.","Sales force expansion on track for Q3 2026; ZYNRELEF prefilled syringe program on schedule with stability data in Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":34711000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99038,"accession_number":"0001193125-26-142947","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Heron Therapeutics amends CEO and executive severance, equity acceleration provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Craig Collard's amended agreement: severance of 1x base salary + bonus (non-CIC) or 2x (CIC), plus equity acceleration.","For performance-based equity granted after April 3, 2026, vesting accelerates at greater of actual performance or target upon qualifying termination.","Similar amendments for CFO Duarte, CDO Forbes, COO Hensley: 12 months pay & equity (non-CIC) or 24 months & full acceleration (CIC).","Agreements add 24-month non-competition and non-solicitation covenants; governing law changed to North Carolina."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114831,"accession_number":"0001193125-26-073502","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Therapeutics reports 2025 net revenue $154.9M, up 7.4%; issues 2026 guidance $173-183M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net revenue $154.9M (+7.4% YoY); Q4 net revenue $40.6M (-0.5% vs Q4 2024).","Acute care franchise grew 65.1% to $49.6M; ZYNRELEF +49%, APONVIE +156%.","Oncology franchise declined 7.8% to $105.3M; CINVANTI -3.3%, SUSTOL -39.9%.","2026 guidance: net revenue $173-183M, adjusted EBITDA $10-20M.","Cash $46.6M; ZYNRELEF J-code effective Oct 2025; prefilled syringe FDA target mid-to-late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":154904000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114830,"accession_number":"0001193125-26-008631","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Heron Therapeutics preliminary Q4 2025 net revenue $40.5M; full-year $154.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue approximately $40.5M, driven by Acute Care franchise momentum.","Full-year 2025 net revenue approximately $154.9M (preliminary, unaudited).","ZYNRELEF net revenue $12.5M in Q4, up ~35% vs Q3 2025, largest product growth.","APONVIE net revenue $3.8M, CINVANTI $22.9M, SUSTOL $1.3M in Q4 2025.","CEO Craig Collard cites continued progress across all aspects of business."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":154904000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131214,"accession_number":"0001193125-25-263617","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Q3 net revenue $38.2M, acute care +67% YoY, FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $38.2M (+16.5% YoY); YTD $114.3M.","ZYNRELEF net revenue $9.3M (+49% YoY); APONVIE $3.0M (+173% YoY).","FY 2025 guidance reaffirmed: net revenue $153-163M, adj. EBITDA $9-13M.","J-code for ZYNRELEF effective Oct 1, 2025; VAN transition complete.","Cash and investments $55.5M as of Sept 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":114316000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131213,"accession_number":"0001193125-25-256300","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Heron Therapeutics appoints Thomas Cusack to board under Rubric Capital agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Cusack appointed to Heron's board effective Oct 27, 2025; term expires at 2026 annual meeting.","Cusack was Managing Director at Starboard Value LP (approx. $9B AUM) from 2011-2025.","Appointment made pursuant to Cooperation Agreement with Rubric Capital Management LP dated Aug 8, 2025.","Cusack will serve on the Nominating and Corporate Governance Committee.","Director compensation follows standard non-employee director program described in April 2025 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131212,"accession_number":"0001193125-25-240253","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Heron shareholders approve share issuances exceeding 19.99% threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Oct 13, 2025, shareholders approved issuance of shares upon conversion of convertible notes due 2031 (89.6M for, 5.6M against).","Shareholders also approved issuance upon automatic conversion of Series A Convertible Preferred Stock (91.5M for, 3.7M against).","Both proposals passed to comply with Nasdaq Listing Rule 5635(d) for potential issuances exceeding 19.99% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147806,"accession_number":"0000950170-25-112048","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Heron Therapeutics signs 111-month lease for 16,837 sq ft HQ in Cary, NC at $614,550/month base rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New headquarters at 25 Fenton Main Street, Cary, NC; approximately 16,837 rentable square feet.","Lease term of ~111 months with one extension option for 84 additional months.","Monthly base rent $614,550.50 for first 12 months, increases by a percentage each subsequent 12-month term.","Base rent and estimated operating costs abated for a certain number of months after commencement.","Tenant receives a one-time right of first refusal on contiguous vacant space."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147805,"accession_number":"0000950170-25-109234","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Heron Therapeutics adopts poison pill to protect $1.37B in NOLs from ownership change","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds ~$1.37B in U.S. federal NOLs as of Dec 31, 2024; plan aims to preserve tax asset.","Plan triggers ownership threshold at 4.99%; effective Aug 14, 2025; expires Aug 14, 2026 unless extended.","Adoption satisfies covenant in Note Purchase Agreement with Rubric Capital Management dated Aug 8, 2025.","Rights plan deters any single investor or group from crossing 4.99% beneficial ownership without Board approval.","Board may exempt acquisitions that do not impair NOL availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147804,"accession_number":"0000950170-25-107416","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"Heron Therapeutics completes comprehensive refinancing, board expansion, and preferred stock issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Refinancing closed Aug 12: repurchased $125M of 2026 notes for cash, exchanged $25M for 16.67M shares; issued $35M notes due 2031 at $33.25M.","Private placement raised ~$27.7M: 13.23M common shares at $1.50 and 524,141 Series A convertible preferred (convertible into 5.24M common at $1.50, subject to stockholder approval).","Cooperation Agreement with Rubric Capital expands board to 7 directors, appoints Rubric nominee, includes standstill until Feb 2026 or 30 days before 2026 annual meeting nomination deadline.","New Series A Convertible Preferred: $15 stated value, conversion price $1.50, senior to common on liquidation/dividends, no voting rights except on adverse charter changes.","Hercules term loan facility amended: up to $150M available with $110M funded on closing, includes PIK interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147803,"accession_number":"0000950170-25-107404","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Heron Therapeutics enters manufacturing/supply deal with Patheon, commits to 38,400 kg through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Framework Agreement with Patheon Austria GmbH & Co KG, a Thermo Fisher unit, for manufacturing and supply of products.","Heron commits to purchase 38,400 kg of Products through December 31, 2026.","Prior agreements terminated; obligations replaced under amended Manufacturing and Supply Agreement.","Patheon to continue stability studies and provide warehousing services for the Products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147802,"accession_number":"0000950170-25-105474","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Heron reports Q2 revenue $37.2M, raises EBITDA guidance; completes capital restructuring reducing debt to $145M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 net revenue $37.2M (+3.3% YoY); year-to-date $76.1M (+7.7%); Acute Care revenue up 55.5% YoY.","2025 Adjusted EBITDA guidance raised to $9M-$13M from $4M-$12M; net revenue guidance reaffirmed $153M-$163M.","Capital restructuring: new $110M facility due 2030; $150M notes exchanged ($125M cash + $25M stock); $35M new convert notes; $27.7M private placement.","Total debt reduced from $175M to $145M; maturities extended to at least 2030, enhancing financial flexibility.","APONVIE unit demand up 19% QoQ; ZYNRELEF unit demand up 6.3% QoQ with new dedicated sales teams launching Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166503,"accession_number":"0000950170-25-087555","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Heron Therapeutics announces 2025 annual meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected all six director nominees: Collard, Dissanaike, Johnson, Kaseta, Morgan, Waage, each receiving >79M votes for.","Ratified WithumSmith+Brown as independent auditor for FY2025: 118.6M votes for, 1.0M against.","Approved non-binding advisory vote on 2024 executive compensation: 79.3M for, 3.5M against.","Adopted annual frequency for future say-on-pay advisory votes: 80.5M for 1-year, 2.2M for 3-year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166502,"accession_number":"0000950170-25-063973","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Therapeutics Q1 2025 net revenue $38.9M, record adj. EBITDA $6.2M, raises FY adj. EBITDA guidance to $4-12M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $38.9M, up 12.2% YoY; acute care franchise up 89.4% driven by ZYNRELEF (+60.4%).","Record Q1 adjusted EBITDA of $6.2M; full-year adj. EBITDA guidance raised to $4-12M from $0-8M.","Settled patent litigation with Mylan on CINVANTI/APONVIE; generic entry agreed for June 1, 2032.","Cash and investments $50.7M; ZYNRELEF prefilled syringe development on track for early 2027 launch.","NOPAIN Act took effect April 1; provides separate Medicare payment for non-opioids like ZYNRELEF."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":38903000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166501,"accession_number":"0000950170-25-063967","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Heron settles patent litigation with Mylan, grants generic license for CINVANTI/APONVIE starting June 2032","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves patent litigations in U.S. District Court for Delaware initiated in Sep 2023 and Jan 2024.","Heron grants Mylan a license to market generic CINVANTI and APONVIE beginning June 1, 2032 (or earlier under certain circumstances).","Patent protection for CINVANTI and APONVIE extends to 2035; license starts ~3 years before expiration.","Parties will file stipulation to dismiss pending litigations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166500,"accession_number":"0000950170-25-059479","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Heron Therapeutics appoints Mark Hensley as COO effective April 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $553,000; target cash bonus of $276,500 (50% of base), prorated for 2025.","Inducement awards: option for 500K shares, 500K RSUs, and performance option for up to 900K shares.","Vesting: option and RSUs vest over 4 years; performance option vests upon stock price goals.","Hensley previously served as CEO of Veloxis Pharmaceuticals from 2021 to 2024.","Awards granted outside 2007 Plan as material inducement under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183929,"accession_number":"0000950170-25-028372","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Q4 net income $3.6M; FY2024 rev $144.2M (+14%); guides 2025 rev $153-163M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 GAAP net income of $3.6M; full-year 2024 adjusted EBITDA of $8.6M.","Full-year 2024 net revenue $144.2M (+14% YoY); Acute Care revenue up 57%, Oncology up 6%.","2025 guidance: net revenue $153-163M, adjusted EBITDA $0-8M.","U.S. District Court upheld CINVANTI patents against Fresenius Kabi; patents expire 2035.","Cash and investments $59.3M; ZYNRELEF VAN launched Dec 2024; Crosslink partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":144285000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183928,"accession_number":"0000950170-25-023958","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Heron Therapeutics extends working capital loan maturity to Sept 2027 or earlier tied to convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity to earlier of Sept 1, 2027, or (if 1.5% convertible notes remain) May 12, 2026.","If note maturity extended beyond Aug 11, 2026, loan due 91 days prior to that extended date.","Amendment with Hercules Capital, Inc. as agent and lender, dated Feb 13, 2025.","Borrower reaffirms security grant and releases claims against lender as part of agreement.","No changes to other terms; conditions precedent include representations and no default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200526,"accession_number":"0000950170-24-139569","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Heron Therapeutics moves HQ from San Diego to Cary, NC effective Jan 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New corporate headquarters at 100 Regency Forest Dr, Suite 300, Cary, NC 27518.","Majority of management team and corporate employees already based in Cary near Research Triangle Park.","CEO Craig Collard says move centralizes operations and supports strategic partnerships.","Company will continue focusing on acute and oncology care therapies from new location."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200525,"accession_number":"0000950170-24-132874","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Heron wins patent lawsuit against Fresenius Kabi over CINVANTI; generic blocked until 2035","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court ruled Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 valid and infringed by Fresenius Kabi's proposed generic CINVANTI.","Effective date of any FDA approval for Fresenius Kabi's ANDA cannot be earlier than September 18, 2035 (patent expiration).","Ruling follows partial summary judgment for infringement in May 2024 and four-day bench trial in June 2024.","Heron will submit proposed final judgment by December 9, 2024.","This protects CINVANTI revenue from generic competition until patents expire in 2035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200524,"accession_number":"0000950170-24-124626","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Therapeutics reports Q3 net product sales of $32.8M; narrows FY2024 guidance to positive Adj EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 acute care franchise net product sales $7.4M (+57% YoY); oncology franchise $25.4M (-5% YoY).","YTD Adjusted EBITDA positive at $1.4M; FY2024 Adj EBITDA guidance narrowed to $2M-$5M (from $(10)-$3M).","ZYNRELEF VAN approved Sep 24, on track for Q4 launch; CMS final rule includes ZYNRELEF for separate payment ($2,267.26 limit) through at least 2027.","Cash and equivalents $70.9M at Sep 30, 2024 vs $80.4M at Dec 31, 2023.","Total net product sales for first 9 months 2024: $103.5M vs $92.8M in prior year period."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":103504000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200523,"accession_number":"0000950170-24-120902","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Heron Therapeutics appoints Michael Kaseta to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Kaseta, CFO/COO of Liquidia, appointed to Heron's Board effective Nov. 4, 2024.","Kaseta brings biopharma finance and commercial expertise; served as CFO at Aerami and Aralez.","Previously CFO of Sanofi North America, managing a $10B business across 100+ products.","Will receive standard non-employee director compensation and enter indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216542,"accession_number":"0000950170-24-091769","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Therapeutics Q2 net product sales $36.0M; narrows 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product sales $36.0M, up from $31.8M YoY; acute care franchise $6.8M, oncology $29.2M.","ZYNRELEF VAN PDUFA goal date set for September 23, 2024; launch expected before year-end.","2024 guidance narrowed: adjusted operating expenses $107-111M (prev $108-116M), adjusted EBITDA ($10) to $3M (prev ($22) to $3M).","ZYNRELEF included in proposed 2025 NOPAIN Act as a qualifying product effective April 1, 2025.","CrossLink partnership expanding; 561 sales representatives trained to promote ZYNRELEF to orthopedic surgeons."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":70694000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216541,"accession_number":"0000950170-24-080026","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Heron Therapeutics announces FDA acceptance of ZYNRELEF VAN supplement; PDUFA goal date September 23, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged receipt of Prior Approval Supplement for ZYNRELEF Vial Access Needle (bupivacaine/meloxicam); PDUFA goal date September 23, 2024.","If approved, VAN would replace vented vial spike, reducing withdrawal time from up to 3 minutes to 20-45 seconds.","VAN expected to be available in Q4 2024 if approved; CrossLink partnership on track to add ~650 representatives by year-end.","CEO Craig Collard expressed optimism that VAN and CrossLink partnership could increase adoption among orthopedic surgeons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236189,"accession_number":"0000950170-24-074952","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Heron shareholders approve increase in authorized shares to 400M and equity plan share expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased by 175M shares from 225M to 400M; effective June 13, 2024.","2007 Plan shares increased by 7.5M (from 39.19M to 46.69M) and ESPP shares by 1.2M (from 2.225M to 3.425M).","All six director nominees elected with ~87M votes for each; auditor ratified with ~114M votes for.","Say-on-pay advisory vote passed with 72.7M for vs 14.4M against; broker non-votes of 29.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236188,"accession_number":"0000950170-24-065636","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Heron submits PAS to FDA for ZYNRELEF Vial Access Needle to simplify preparation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PAS seeks FDA approval to replace current vented vial spike with new Vial Access Needle (VAN).","VAN reduces product withdrawal time from up to 3 minutes to 20-45 seconds, simplifying aseptic preparation.","Heron expects FDA review action date within 4-6 months; decision pending.","ZYNRELEF is already approved for postoperative pain; VAN addresses healthcare provider feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236187,"accession_number":"0000950170-24-053963","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Q1 2024 net product sales $34.7M (+17% YoY); net loss per share improves to $(0.02)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $34.7M vs $29.6M YoY; net loss per share $(0.02) vs $(0.27).","Gross margin improved to 76% in Q1 2024 from 43% in Q1 2023.","ZYNRELEF net sales $5.0M (+43% YoY); FDA expanded indication approved Jan 23, 2024, covering soft tissue and orthopedic procedures.","Reaffirmed FY2024 guidance: product revenues $138-158M, adjusted operating expenses $108-116M, adjusted EBITDA $(22)-$3M.","Partnership with CrossLink Life Sciences; 191 CrossLink sales reps trained and engaged with physicians."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":34670000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253888,"accession_number":"0001193125-24-073897","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Heron Therapeutics designates Ira Duarte as principal accounting officer, replacing Lisa Peraza","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ira Duarte appointed principal accounting officer effective March 29, 2024, succeeding Lisa Peraza.","Lisa Peraza will remain as chief accounting officer until her employment ends on the effective date.","No additional compensation or adjustments for Duarte in connection with the new role.","Duarte already serves as EVP and CFO; no family relationships or related party transactions with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253887,"accession_number":"0000950170-24-029926","cik":818033,"company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Heron Therapeutics Q4 2023: oncology revenue $107.9M, ZYNRELEF record $5.6M, 2024 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 oncology care franchise revenue $107.9M exceeded guidance; net product sales up 11% YoY.","ZYNRELEF Q4 net product sales record $5.6M (up from $3.9M Q4 2022); acute care franchise sales $6.1M.","Gross margin improved to 71% in Q4 from 58% a year ago; cash and equivalents $80.4M at year-end.","FDA approved expanded ZYNRELEF label covering ~13M annual procedures; CrossLink partnership adds up to 650 sales reps.","2024 guidance: product revenues $138-158M, adjusted EBITDA $(22)-$3M; VAN program PAS submission on track for Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":172206375.43937507,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}